XOMA 358 Hyperinsulinemic Hypoglycemia Treatment 2017

XOMA presented Phase 1 proof-of-concept data for 358, a first-in-class treatment for hyperinsulinemic hypoglycemia (HH). The treatment demonstrated efficacy in raising glucose levels and reducing hypoglycemic episodes across 14 congenital HH and 13 post-bariatric surgery patients, with multi-dose studies approved in the UK for pediatric patients.